Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer

Wei Ching Chen, Yung Sheng Chang, Hui Ping Hsu, Meng Chi Yen, Hau Lun Huang, Chien Yu Cho, Chih Yang Wang, Tzu Yang Weng, Po Ting Lai, Ching Shih Chen, Yih Jyh Lin, Ming Derg Lai

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

CD90 is used as a marker for cancer stem cell in liver cancer. We aimed to study the mechanism by which CD90 promoted liver cancer progression and identify the new therapeutic targets on CD90 signal pathway. Ectopic expression of CD90 in liver cancer cell lines enhanced anchorage-independent growth and tumor progression. Furthermore, CD90 promoted sphere formation in vitro and upregulated the expression of the cancer stem cell marker CD133. The CD133 expression was higher in CD45-CD90+ cells in liver cancer specimen. The natural carcinogenic molecules TGF-β-1, HGF, and hepatitis B surface antigen increased the expression of CD90 and CD133. Inhibition of CD90 by either shRNA or antibody attenuated the induction of CD133 and anchorage-independent growth. Lentiviral delivery of CD133 shRNA abolished the tumorigenicity induced by CD90. Ectopic expression of CD90 induced mTOR phosphorylation and AMPK dephosphorylation. Mutation of integrin binding-RLD domain in CD90 attenuated the induction of CD133 and anchorage-independent growth. Similar results were observed after silencing β3 integrin. Signaling analyses revealed that AMPK/mTOR and β3 integrin were required for the induction of CD133 and tumor formation by CD90. Importantly, the energy restriction mimetic agent OSU-CG5 reduced the CD90 population in fresh liver tumor sample and repressed the tumor growth. In contrast, sorafenib did not decrease the CD90+ population. In conclusion, the signal axis of CD90-integrin-mTOR/AMPK-CD133 is critical for promoting liver carcinogenesis. Molecules inhibiting the signal axis, including OSU-CG5 and other inhibitors, may serve as potential novel cancer therapeutic targets in liver cancer.

Original languageEnglish
Pages (from-to)42923-42937
Number of pages15
JournalOncotarget
Volume6
Issue number40
DOIs
Publication statusPublished - Jan 1 2015
Externally publishedYes

Fingerprint

Xenograft Model Antitumor Assays
Thy-1 Antigens
CD Antigens
Molecular Targeted Therapy
Gene Knockdown Techniques
Thiazolidinediones
Inbred NOD Mouse
AMP-Activated Protein Kinases
SCID Mice
Liver Neoplasms
Tumor Cell Line
Integrins
Antineoplastic Agents
Small Interfering RNA
Transfection
Hepatocellular Carcinoma
Signal Transduction
Glycoproteins
Flow Cytometry
Carcinogenesis

Keywords

  • AMPK
  • Cancer stem cell marker
  • Integrin
  • MTOR
  • OSU-CG5

ASJC Scopus subject areas

  • Oncology

Cite this

Chen, W. C., Chang, Y. S., Hsu, H. P., Yen, M. C., Huang, H. L., Cho, C. Y., ... Lai, M. D. (2015). Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer. Oncotarget, 6(40), 42923-42937. https://doi.org/10.18632/oncotarget.5976

Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer. / Chen, Wei Ching; Chang, Yung Sheng; Hsu, Hui Ping; Yen, Meng Chi; Huang, Hau Lun; Cho, Chien Yu; Wang, Chih Yang; Weng, Tzu Yang; Lai, Po Ting; Chen, Ching Shih; Lin, Yih Jyh; Lai, Ming Derg.

In: Oncotarget, Vol. 6, No. 40, 01.01.2015, p. 42923-42937.

Research output: Contribution to journalArticle

Chen, WC, Chang, YS, Hsu, HP, Yen, MC, Huang, HL, Cho, CY, Wang, CY, Weng, TY, Lai, PT, Chen, CS, Lin, YJ & Lai, MD 2015, 'Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer', Oncotarget, vol. 6, no. 40, pp. 42923-42937. https://doi.org/10.18632/oncotarget.5976
Chen WC, Chang YS, Hsu HP, Yen MC, Huang HL, Cho CY et al. Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer. Oncotarget. 2015 Jan 1;6(40):42923-42937. https://doi.org/10.18632/oncotarget.5976
Chen, Wei Ching ; Chang, Yung Sheng ; Hsu, Hui Ping ; Yen, Meng Chi ; Huang, Hau Lun ; Cho, Chien Yu ; Wang, Chih Yang ; Weng, Tzu Yang ; Lai, Po Ting ; Chen, Ching Shih ; Lin, Yih Jyh ; Lai, Ming Derg. / Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer. In: Oncotarget. 2015 ; Vol. 6, No. 40. pp. 42923-42937.
@article{29cd76476ecb48f2912435a0c532f2a6,
title = "Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer",
abstract = "CD90 is used as a marker for cancer stem cell in liver cancer. We aimed to study the mechanism by which CD90 promoted liver cancer progression and identify the new therapeutic targets on CD90 signal pathway. Ectopic expression of CD90 in liver cancer cell lines enhanced anchorage-independent growth and tumor progression. Furthermore, CD90 promoted sphere formation in vitro and upregulated the expression of the cancer stem cell marker CD133. The CD133 expression was higher in CD45-CD90+ cells in liver cancer specimen. The natural carcinogenic molecules TGF-β-1, HGF, and hepatitis B surface antigen increased the expression of CD90 and CD133. Inhibition of CD90 by either shRNA or antibody attenuated the induction of CD133 and anchorage-independent growth. Lentiviral delivery of CD133 shRNA abolished the tumorigenicity induced by CD90. Ectopic expression of CD90 induced mTOR phosphorylation and AMPK dephosphorylation. Mutation of integrin binding-RLD domain in CD90 attenuated the induction of CD133 and anchorage-independent growth. Similar results were observed after silencing β3 integrin. Signaling analyses revealed that AMPK/mTOR and β3 integrin were required for the induction of CD133 and tumor formation by CD90. Importantly, the energy restriction mimetic agent OSU-CG5 reduced the CD90 population in fresh liver tumor sample and repressed the tumor growth. In contrast, sorafenib did not decrease the CD90+ population. In conclusion, the signal axis of CD90-integrin-mTOR/AMPK-CD133 is critical for promoting liver carcinogenesis. Molecules inhibiting the signal axis, including OSU-CG5 and other inhibitors, may serve as potential novel cancer therapeutic targets in liver cancer.",
keywords = "AMPK, Cancer stem cell marker, Integrin, MTOR, OSU-CG5",
author = "Chen, {Wei Ching} and Chang, {Yung Sheng} and Hsu, {Hui Ping} and Yen, {Meng Chi} and Huang, {Hau Lun} and Cho, {Chien Yu} and Wang, {Chih Yang} and Weng, {Tzu Yang} and Lai, {Po Ting} and Chen, {Ching Shih} and Lin, {Yih Jyh} and Lai, {Ming Derg}",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.5976",
language = "English",
volume = "6",
pages = "42923--42937",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "40",

}

TY - JOUR

T1 - Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer

AU - Chen, Wei Ching

AU - Chang, Yung Sheng

AU - Hsu, Hui Ping

AU - Yen, Meng Chi

AU - Huang, Hau Lun

AU - Cho, Chien Yu

AU - Wang, Chih Yang

AU - Weng, Tzu Yang

AU - Lai, Po Ting

AU - Chen, Ching Shih

AU - Lin, Yih Jyh

AU - Lai, Ming Derg

PY - 2015/1/1

Y1 - 2015/1/1

N2 - CD90 is used as a marker for cancer stem cell in liver cancer. We aimed to study the mechanism by which CD90 promoted liver cancer progression and identify the new therapeutic targets on CD90 signal pathway. Ectopic expression of CD90 in liver cancer cell lines enhanced anchorage-independent growth and tumor progression. Furthermore, CD90 promoted sphere formation in vitro and upregulated the expression of the cancer stem cell marker CD133. The CD133 expression was higher in CD45-CD90+ cells in liver cancer specimen. The natural carcinogenic molecules TGF-β-1, HGF, and hepatitis B surface antigen increased the expression of CD90 and CD133. Inhibition of CD90 by either shRNA or antibody attenuated the induction of CD133 and anchorage-independent growth. Lentiviral delivery of CD133 shRNA abolished the tumorigenicity induced by CD90. Ectopic expression of CD90 induced mTOR phosphorylation and AMPK dephosphorylation. Mutation of integrin binding-RLD domain in CD90 attenuated the induction of CD133 and anchorage-independent growth. Similar results were observed after silencing β3 integrin. Signaling analyses revealed that AMPK/mTOR and β3 integrin were required for the induction of CD133 and tumor formation by CD90. Importantly, the energy restriction mimetic agent OSU-CG5 reduced the CD90 population in fresh liver tumor sample and repressed the tumor growth. In contrast, sorafenib did not decrease the CD90+ population. In conclusion, the signal axis of CD90-integrin-mTOR/AMPK-CD133 is critical for promoting liver carcinogenesis. Molecules inhibiting the signal axis, including OSU-CG5 and other inhibitors, may serve as potential novel cancer therapeutic targets in liver cancer.

AB - CD90 is used as a marker for cancer stem cell in liver cancer. We aimed to study the mechanism by which CD90 promoted liver cancer progression and identify the new therapeutic targets on CD90 signal pathway. Ectopic expression of CD90 in liver cancer cell lines enhanced anchorage-independent growth and tumor progression. Furthermore, CD90 promoted sphere formation in vitro and upregulated the expression of the cancer stem cell marker CD133. The CD133 expression was higher in CD45-CD90+ cells in liver cancer specimen. The natural carcinogenic molecules TGF-β-1, HGF, and hepatitis B surface antigen increased the expression of CD90 and CD133. Inhibition of CD90 by either shRNA or antibody attenuated the induction of CD133 and anchorage-independent growth. Lentiviral delivery of CD133 shRNA abolished the tumorigenicity induced by CD90. Ectopic expression of CD90 induced mTOR phosphorylation and AMPK dephosphorylation. Mutation of integrin binding-RLD domain in CD90 attenuated the induction of CD133 and anchorage-independent growth. Similar results were observed after silencing β3 integrin. Signaling analyses revealed that AMPK/mTOR and β3 integrin were required for the induction of CD133 and tumor formation by CD90. Importantly, the energy restriction mimetic agent OSU-CG5 reduced the CD90 population in fresh liver tumor sample and repressed the tumor growth. In contrast, sorafenib did not decrease the CD90+ population. In conclusion, the signal axis of CD90-integrin-mTOR/AMPK-CD133 is critical for promoting liver carcinogenesis. Molecules inhibiting the signal axis, including OSU-CG5 and other inhibitors, may serve as potential novel cancer therapeutic targets in liver cancer.

KW - AMPK

KW - Cancer stem cell marker

KW - Integrin

KW - MTOR

KW - OSU-CG5

UR - http://www.scopus.com/inward/record.url?scp=84952360519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952360519&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.5976

DO - 10.18632/oncotarget.5976

M3 - Article

VL - 6

SP - 42923

EP - 42937

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 40

ER -